Forxiga smile with first PMS result conducted on large Koreans

The post-marketing surveillance(PMS) result of ‘Forxiga(generic name: dapagliflozin),’ a SGLT-2 inhibitor whose research was conducted on 1,500 Korean diabetes type 2 patients, has been released. The 24-week researchees’ glycated hemoglobin and weight ware researched to drop 0.87% and 1.71kg down.

It was studied the number of expected adverse reactions, such as urinary tract infection and geni...